SCHEMBL4334732

SCHEMBL4334732

Cc1ccc(N2N=C(c3ccccc3)CC2=O)cc1C

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 5/20 0.62
TDP1 Q9NUW8 4/20 0.62
KMT2A Q03164 7/20 0.59
MAPT P10636 5/20 0.59
MEN1 O00255 5/20 0.59
NPSR1 Q6W5P4 1/20 0.59
L3MBTL1 Q9Y468 1/20 0.59
APP P05067 4/20 0.56
KDM4E B2RXH2 3/20 0.55
CD274 Q9NZQ7 4/20 0.54
PDCD1 Q15116 3/20 0.54
ALDH1A1 P00352 1/20 0.50
CYP1A2 P05177 1/20 0.50
CHRM2 P08172 1/20 0.50
CYP3A4 P08684 1/20 0.50
CHRM1 P11229 1/20 0.50
TSHR P16473 1/20 0.50
PTGS1 P23219 1/20 0.50
DRD3 P35462 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4344590 0.87 KMT2A (0.47) GAATDP1KMT2AMAPTMEN1
SCHEMBL4760027 0.86 MEN1 (0.68) GAATDP1KMT2AMAPTMEN1
SCHEMBL9383465 0.85 KMT2A (0.70) GAATDP1KMT2AMAPTMEN1
SCHEMBL2604371 0.82 MEN1 (0.74) GAATDP1KMT2AMAPTMEN1
SCHEMBL4339163 0.81 GAA (0.41) GAATDP1KMT2AMAPTMEN1
SCHEMBL4344114 0.81 GAA (0.44) GAATDP1KMT2AMAPTMEN1
SCHEMBL4345470 0.81 CD274 (0.48) GAATDP1KMT2AMAPTMEN1
SCHEMBL4661656 0.80 CD274 (0.68) GAATDP1KMT2AMAPTMEN1
SCHEMBL29546133 0.80 MAPT (0.63) GAATDP1KMT2AMAPTMEN1
SCHEMBL4663211 0.80 MAPT (0.63) GAATDP1KMT2AMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130078213-A1 THROMBOPOIETIN MIMETICS GLAXOSMITHKLINE LLC 2013-03-28 US disclosed
EP-1889838-B1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORP (US) 2009-10-14 EP disclosed
EP-1889838-A1 Thrombopoietin mimetics SmithKline Beecham Corporation (US) 2008-02-20 EP disclosed
EP-1864981-A1 Thrombopoietin mimetics SmithKline Beecham Corporation (US) 2007-12-12 EP disclosed
US-20070129338-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION 2007-06-07 US disclosed
US-20040019190-A1 Thrombopoietin mimetics NOVARTIS AG (CH) 2004-01-29 US disclosed
EP-1294378-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2004-01-28 EP disclosed
EP-1294378-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-26 EP disclosed
WO-2001089457-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2001-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129338-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK GAA 2853/4885TDP1 2922/4885KMT2A 1838/4885
US-20130078213-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK GAA 2853/4885TDP1 2922/4885KMT2A 1838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.